Sugi Predict

Sugi Predict / Compounds / SCHEMBL695658

SCHEMBL695658

SCHEMBL695658

Fc1ccc(S)c(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.47
▸ TRPA1 O75762 2/20 0.37
▸ MRGPRX4 Q96LA9 1/20 0.36
▸ AR P10275 5/20 0.35
▸ HCAR1 Q9BXC0 1/20 0.35
▸ GLA P06280 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ SLC6A2 P23975 2/20 0.33
▸ SLC6A4 P31645 2/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29708357 1.00 IDO1 (0.47) IDO1TRPA1MRGPRX4ARHCAR1
SCHEMBL7601736 0.79 IDO1 (0.50) IDO1TRPA1ARHCAR1GLA
SCHEMBL1912818 0.78 IDO1 (0.46) IDO1TRPA1MRGPRX4ARHCAR1
SCHEMBL29775945 0.77 IDO1 (0.48) IDO1AR
SCHEMBL7265211 0.77 IDO1 (0.48) IDO1AR
SCHEMBL30721709 0.75 CES2 (0.52) ARTSHR
SCHEMBL3962902 0.75 CES2 (0.52) ARTSHR
SCHEMBL5948813 0.73 IDO1 (0.46) IDO1TRPA1MRGPRX4ARHCAR1
SCHEMBL5948815 0.73 IDO1 (0.46) IDO1TRPA1MRGPRX4ARHCAR1
SCHEMBL172998 0.73 IDO1 (0.46) IDO1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12331022-B2 Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors MERCK SHARP & DOHME LLC (US) 2025-06-17 — — US disclosed
US-20240269293-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF OD THERAPEUTICS LIMITED (CN) 2024-08-15 — — US disclosed
EP-4400500-A1 HALOGEN-SUBSTITUTED PYRIDAZINONE COMPOUND AND APPLICATION THEREOF Medshine Discovery Inc. (CN) 2024-07-17 — — EP disclosed
EP-4313154-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF OD Therapeutics Limited (HK) 2024-02-07 — — EP disclosed
CN-117355337-A Protein-macromolecule conjugates and methods of use thereof 奥迪曼药业科技有限公司 2024-01-05 — — CN disclosed
CN-116731013-A Heterocyclic compound, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-09-12 — — CN disclosed
US-20230257382-A1 HETEROCYCLIC COMPOUND AND USE THEREOF WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2023-08-17 — — US disclosed
US-20230257382-A1 HETEROCYCLIC COMPOUND AND USE THEREOF WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2023-08-17 — — US disclosed
US-20220401561-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF AJ SCIENCES (YIXING) CO., LTD (CN) 2022-12-22 — — US disclosed
CN-114630818-A Protein-macromolecule conjugates and methods of use thereof 北京轩义医药科技有限公司 2022-06-14 — — CN disclosed
CN-102459162-A Novel cyclopentane derivatives HOFFMANN LA ROCHE 2012-05-16 — — CN disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 — — US disclosed
EP-2440521-A1 NOVEL CYCLOPENTANE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-04-18 — — EP disclosed
CN-102405211-A Proline derivatives as cathepsin inhibitors HOFFMANN LA ROCHE 2012-04-04 — — CN disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 — — EP disclosed
US-7893099-B2 Cyclopentane derivatives HOFFMAN-LA ROCHE INC. (US) 2011-02-22 — — US disclosed
WO-2010142650-A1 NOVEL CYCLOPENTANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 — — WO disclosed
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 — — US disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 — — WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12331022-B2 Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors CHRNA7, CHRNA5, CHRNA2 IDO1 1452/4885TRPA1 676/4885MRGPRX4 2502/4885
US-20240269293-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF CD44, MACROD1, MSN IDO1 4570/4885TRPA1 4884/4885MRGPRX4 2879/4885
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES TBXA2R, ADORA1, CNR1 IDO1 936/4885TRPA1 726/4885MRGPRX4 132/4885
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 IDO1 1249/4885TRPA1 2495/4885MRGPRX4 356/4885
US-20220401561-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF CD44, SSB, DNPEP IDO1 4424/4885TRPA1 4872/4885MRGPRX4 2272/4885
US-20230257382-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TRPC5, TRPC1, GOT1 IDO1 184/4885TRPA1 44/4885MRGPRX4 570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.